The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation
Penn collection
Degree type
Discipline
Subject
Pharmacy Administration, Policy and Regulation
Funder
Grant number
License
Copyright date
Distributor
Related resources
Author
Contributor
Abstract
This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug reactions (ADRs) by modeling the interaction between a regulator (the FDA) and a pharmaceutical firm. Promotion-driven market expansions enhance profitability yet may involve the risk of inappropriate drug prescriptions, leading to regulatory actions against the firm. We empirically test the relationship between drug promotion and reporting of ADRs using an innovative combination of commercial data on pharmaceutical promotion and FDA data on regulatory interventions and ADRs. We provide some evidence that increased levels of promotion and advertising lead to increased reporting of ADRs for certain conditions.